Urinary bladder paraganglioma (paraganglioma) is a rare tumor of chromaffin cells of the sympathetic system of the urinary bladder wall. We studied 14 cases of this entity and investigated the usefulness of SDHB protein staining by immunohistochemistry (IHC) as a diagnostic tool to identify patients with bladder paragangliomas that could be associated with SDHB gene mutations, as these patients have a more aggressive disease. Eleven tumors from these patients were stained by IHC. Six of 11 tumors were negative for SDHB staining by IHC with no cytoplasmic staining in tumor cells when compared with normal tissues. Five of these 6 negative cases were confirmed to be positive for germline SDHB mutations. One case showed negative staining and no germline SDHB mutation; however, further investigation of the tumor revealed a somatic SDHB gene deletion. The remaining 5 cases showed strong cytoplasmic staining, but they were negative for the presence of SDHB mutation. They were found to be either sporadic tumors or part of von Hippel-Lindau syndrome. Staining for SDHA was positive in all cases. Our study confirms that there is very good correlation between the presence of an SDHB mutation, whether germline or sporadic, and negative SDHB IHC staining in urinary bladder paragangliomas, and this is the first study to demonstrate that somatic mutations can be recognized by IHC staining.
BACKGROUND
Urinary bladder paraganglioma (paraganglioma) is an unusual tumor that originates from chromaffin cells of the sympathetic system of the urinary bladder wall. 1 It accounts for <0.05% of all bladder neoplasms, often occurs in young adults with a female prevalence, and can be sporadic or part of hereditary syndromes such as von Hippel-Lindau (VHL), multiple endocrine neoplasia, and succinate dehydrogenase (SDH) syndromes. 2 Clinically, these patients present more frequently with hematuria, but they may present with catecholamine-related symptoms, such as hypertension, tachyarrhythmia, sweating, headache, and micturition syncope. These tumors are histologically distinct from a high-grade urothelial carcinoma and carcinoid tumors, with a classic zellballen pattern of growth embedded in a highly vascular fibrous network. 3, 4 Several studies have explored the usefulness of different morphologic, immunohistochemical (IHC), and other markers of malignancy, [5] [6] [7] [8] but there is still no unanimous consensus.
Bladder paragangliomas can occur as a component of hereditary tumor syndromes, which have been well defined in the last decade. 2 One of these familial paraganglioma syndromes is associated with distinct genetic mutations in 1 of the 4 subunit genes of the SDH (SDHA, B, C, or D), an enzyme complex that is involved in the electron transport chain and in the Krebs cycle. These genes act as tumor-suppressor genes and conform to the Knudson 2-hit model of tumorigenesis.
In particular, germline mutations in the SDHB gene have been associated with hereditary forms of bladder paraganglioma and their more aggressive and metastatic behavior. Somatic SDHB mutations have also been described. 9 As SDHB mutations are associated with the highest rate of malignancy (> 50%), 10, 11 recognition and accurate tumor characterization for SDHB gene mutation status are of utmost importance for the management, prognosis, and proper follow-up of these patients and their families. This strongly suggests that ancillary studies are important in distinguishing these tumors from other hereditary paragangliomas.
Therefore, in the present study we investigated the usefulness of SDHB protein presence or absence as a diagnostic tool to identify bladder paragangliomas associated with SDHB gene mutations using staining by IHC in paraffin-embedded sections.
MATERIALS AND METHODS
Paraganglioma tumor tissue was obtained from patients accepted for protocol evaluation at the National Institutes of Health (NIH), in accordance with the principles and procedures outlined in the NIH IRB Guidelines, and this was approved by the Institutional Review Board of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), NIH. All patients signed an IRB-approved consent that allowed for the collection of tissue samples.
Fourteen cases of urinary bladder paragangliomas were studied. Tumors were morphologically evaluated and stained for proliferative markers (MIB-1), chromogranin, and synaptophysin. Eleven cases were stained for SDHA and SDHB protein expression by IHC. One polyclonal antibody (HPA002868, Sigma-Aldrich) was used to recognize the target human protein for SDHB (recognizing the C-terminal).
Immunohistochemistry
Protein expression of SDHA and SDHB was evaluated by IHC using a mouse monoclonal antibody against human SDHA (Abcam) or a polyclonal antibody against SDHB protein (Santa Cruz Biotechnology). Paraffin-embedded sections (5 mm) were deparaffinized in 3 xylene baths and rehydrated in graded alcohols. Tissue sections were microwaved in Tris-EDTA buffer (10 mM Tris, 1 mM EDTA) for 20 minutes and then allowed to cool down for another 20 minutes. Endogenous peroxidase was blocked with 0.3% hydrogen peroxide in phosphate-buffered saline for 15 minutes. Sections were then incubated with protein blocking buffer at room temperature for 30 minutes, followed by incubation at 371C for 1 hour with the SDHA or SDHB antibody (1:100 final concentration). For negative controls, sections were incubated in parallel with TBST buffer instead of primary antibodies. After rinsing, the sections were incubated with a peroxidase-labeled polymer conjugated to goat anti-mouse and goat anti-rabbit immunoglobulins as secondary antibody for 45 minutes (EnVision Dual Link System-HRP Kit; Dako Cytomation, Carpinteria, CA). The staining was visualized with 3,3 0 -diaminobenzidine as chromogen, and slides were counterstained with hematoxylin, dehydrated, and finally mounted. IHC was interpreted as positive or negative when cytoplasmic staining was identified (see the Results section). For MIB-1 IHC, the specific antibody was used at 1:200 concentration, for 20 minutes in citrate pH 6.0. Antigen retrieval was obtained in a pressure cooker, followed by 32 minutes primary incubation on Ventana Benchmark XT with Ultra View DAB kit detection.
Sequencing Analysis
Detection of large deletions was performed using a combination of multiplex ligation-dependent probe amplification (MLPA)-based probes and Luminex FlexMap technology. Seventeen sets of hybridization probes were designed to cover all 3 genes (SDHB, SDHC, SDHD), and 5 sets of hybridization probes were designed for housekeeping gene controls. The upstream probe of each set contained a universal 5 0 M13 sequence while the downstream probe carried a specific sequence designed to bind to an individual FlexMap bead, and a universal M13-3 0 tail. Following ligation and amplification, polymerase chain reaction products were captured on Luminex FlexMap beads carrying the complementary antitags to the 3 0 probe tags. The median fluorescent intensity signal is detected. For each probe, significant deviations from a 1:1 ratio between signals from normal control samples and patient samples indicate possible deletions or insertions/duplications. Figure 2 shows the peak ratios of averaged control signal to the signal generated in a run by control samples and the response ratios observed in the sample of an M865 patient with a complete deletion of the SDHB gene (A1). The horizontal green lines and the green shaded area on each graph indicate the expected normal range for the signal ratios (ratio between 0.8 and 1.2).
RESULTS

IHC Analysis
Six of the 11 tumors stained were negative for SDHB staining by IHC showing no cytoplasmic staining in the tumor cells ( Fig. 1 ) when compared with the normal tissues. Of these 6 negative staining cases, 5 were confirmed positive for germline SDHB mutations, the remaining case was negative for SDHB germline mutation but further investigation confirmed an SDHB somatic mutation as described below. Five of the 11 stained cases showing strong cytoplasmic staining were negative for the presence of SDHB mutations, but 4 were positive for VHL gene mutation (and 1 unknown). All the cases stained with SDHA by IHC were positive in our cohort ( Fig. 1 ). An illustrative micrograph from each staining profile is represented in Figure 1 , including staining for SDHB and SDHA and a confirmatory IHC stain for chromogranin. Table 1 summarized basic clinical characteristics of the patients evaluated in this study. A predominance of female individuals is represented in our data set, with a cohort of 11 women (78%) and 3 men (22%). This is consistent with the known female predominance reported in the literature. The mean age at the time of diagnosis was 31 years, with a range spanning from 6 to 64 years. This is also in line with the younger age of onset of these types of tumor as reported in the literature.
Clinical Characteristics
The patients in our cohort were evaluated for germline mutation analysis of the most common hereditary paraganglioma syndromes. Of these, 4 patients were found to have VHL mutations, 6 patients had SDHB mutations (5 were available for staining). One patient was known negative for the germline mutation, but it proved to have the somatic mutation. The remaining 4 patients had germline mutations in the VHL gene, and 1 was sporadic.
of the cases with available size information (11) was 2.59 cm, with an SD of 2.09 cm. Two cases were excluded because only biopsies were available and not the full specimen, and for 1 case we were not able to have sufficient information. The mean tumor size was similar between the patients with VHL and SDHB germline mutations. We identified lymphovascular invasion in 2 cases, but none of the cases in our cohort had evidence of tumor necrosis or mitotic activity. MIB-1 stains for the Ki67 proliferation index were performed in 11 cases. Evaluation of Ki67 was done following similar criteria for the other neuroendocrine tumors. We found that 8 cases had low proliferation index (up to 2%), and 3 cases had an intermediate proliferation index (> 2%). The cases with a higher proliferation index and larger size and vascular invasion were patients carrying an SDHB germline mutation.
Sequencing Analysis
Only 1 case showed negative staining and no germline SDHB mutation; however, further investigation of the tumor using complete genotyping of the SDHB gene using MLPA revealed a somatic SDHB deletion (Fig. 2) .
CONCLUSIONS
Urinary bladder paragangliomas are rare tumors, representing 1% of all paragangliomas and 0.05% of all bladder tumors. However, the urinary bladder is a common site of paragangliomas associated with hereditary syndromes. Paragangliomas associated with SDHB syndrome have been known to have a more aggressive behavior, and potential for metastasis 12 -hence the importance of recognizing patients who present with these tumors so that proper treatment and genetic counseling can be established. Several markers have been proposed, and some authors have tentatively explored scoring systems to predict malignant behavior. 7, 8 Up to 30% of all paragangliomas present as hereditary with specific germline mutations. Recently, a single aberrant somatic mutation has been described in a bladder wall paraganglioma: a C299T mutation was found in the SDHB gene in tumor DNA and not in the normal tissue from the same patient, excluding an SDHB germline mutation. 9 This mutation results in the change of a nonpolar to an uncharged polar side chain in a highly conserved region in the SDHB protein, with potential consequence on the protein folding and overall structure. This discovery stressed the importance of studying the SDHB gene not only in inherited but also in sporadic paragangliomas. Building on these and other findings, here we identified a patient with a negative SDHB germline mutation and negative IHC SDHB staining for further analysis using complete genotyping of the SDHB gene using MLPA. We found that the patient carried a somatic SDHB gene deletion. Staining by IHC for SDHB is an easy and practical way to identify patients with both germline and somatic mutations. Our findings are in agreement with a recent report, 13 which has identified 3 of 11 patients with loss of SDHB staining. One of the 3 patients also had a loss of SDHA mutation. We also stained our cohort for SDHA, but we did not find loss of SDHA staining in any of our patients.
Our study shows the importance of sporadic mutations, usually more difficult to discover because no family history is present and no specific tests are performed on the patient. Moreover, we emphasize the importance to have SDHB stains in a pathology IHC laboratory, considering the growing number of diseases in which staining for SDHB can be a useful diagnostic or prognostic tool.
We evaluated for the proliferation index using the MIB-1 stain (ki67) and found that 8 cases had a low Ki67 rate (up to 2%), and 3 cases had an intermediate Ki67 rate (> 2%). The 3 cases with an intermediate Ki67 rate were patients with confirmed SDHB germline mutations. We have previously reported the importance of MIB-1/ Ki67 as a prognostic marker in other tumors. 14 However, in this case, the small number of specimens is too limited for a conclusion, although there may be a correlation.
Our results indicate a direct correlation between the presence of an SDHB mutation, whether germline or somatic, and negative SDHB IHC staining in urinary bladder paragangliomas. These findings strongly support the use of SDHB IHC in the diagnostic algorithm ( Fig. 3 ) to recognize paraganglioma of urinary bladder associated with SDHB syndrome that may have potential for an aggressive behavior. Identification of these patients will also allow for family screening, genetic counseling, and establishment of proper therapies. In most institutions staining for SDHB is ordered by pathologists, as clinicians may not be aware that IHC for SDHB is available. In conclusion, if questions arise, it may be recommended that the pathologist consult with the clinician who can discuss the situation with the patient. Genetic testing should be recommended for cases that stain negative.
